United States Biotechnology & Medical Research

Onkure Therapeutics Inc (OKUR)

Track

Onkure Therapeutics Inc. executives, specifically the CEO and CFO, executed two planned sales totaling approximately 1,710 USD over the past ninety days. These divestments occurred amidst a 20.3% stock price increase. The company's latest earnings report showed a 46.6% positive surprise, reflecting recent performance trends within this healthcare entity.
Ticker: OKUR Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Onkure Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.6
Saccomano Nicholas A President and CEO Executive Director
Transaction date
Planned sale
Price
393.65
Quantity 63,680 -3.4%
Value US$3,859,986
3.7
Leverone Jason A. Chief Financial Officer Officer
Transaction date
Planned sale
Price
63.93
Quantity 56,795 +3.9%
Value US$306,293
3.7
Leverone Jason A. Chief Financial Officer Officer
Transaction date
Sale
Price
307.58
Quantity 52,482 -11.1%
Value US$3,346,311
3.6
Saccomano Nicholas A President and CEO Executive Director
Transaction date
Sale
Price
4.16
Quantity 86 -1.2%
Value US$357
3.6
Saccomano Nicholas A President and CEO Executive Director
Transaction date
Planned sale
Price
2.97
Quantity 87 -1.2%
Value US$258
3.7
Leverone Jason A. Chief Financial Officer Officer
Transaction date
Planned sale
Price
2.97
Quantity 302 -1.8%
Value US$896
3.7
Leverone Jason A. Chief Financial Officer Officer
Transaction date
Sale
Price
2.62
Quantity 303 -2.3%
Value US$795
3.6
Saccomano Nicholas A President and CEO Executive Director
Transaction date
Sale
Price
2.62
Quantity 88 -2.4%
Value US$231
3.6
Saccomano Nicholas A President and CEO Executive Director
Transaction date
Sale
Price
2.38
Quantity 88 -2.4%
Value US$210
3.7
Leverone Jason A. Chief Financial Officer Officer
Transaction date
Sale
Price
2.38
Quantity 303 -2.3%
Value US$722
3.2
ACORN BIOVENTURES, L.P. Large shareholder
Transaction date
Purchase
Price
1.85
Quantity 1,129,730 +inf%
Value US$2,090,000
3.2
ACORN BIOVENTURES, L.P. Large shareholder
Transaction date
Purchase
Price
1.85
Quantity 270,270 +18.8%
Value US$500,000
3.6
Saccomano Nicholas A President and CEO Executive Director
Transaction date
Sale
Price
2.67
Quantity 516 -12.3%
Value US$1,378
3.7
Leverone Jason A. Chief Financial Officer Officer
Transaction date
Sale
Price
2.67
Quantity 1,844 -12.3%
Value US$4,925
3.6
Saccomano Nicholas A President and CEO Executive Director
Transaction date
Sale
Price
3.33
Quantity 358 -7.9%
Value US$1,191
3.7
Leverone Jason A. Chief Financial Officer Officer
Transaction date
Sale
Price
3.33
Quantity 1,278 -7.8%
Value US$4,253
2.9
Leonard Braden Michael Large shareholder
Transaction date
Purchase
Price
1.50
Quantity 68,746 +2.0%
Value US$102,872
2.9
Leonard Braden Michael Large shareholder
Transaction date
Purchase
Price
1.41
Quantity 29,600 +0.9%
Value US$41,866
2.9
Leonard Braden Michael Large shareholder
Transaction date
Purchase
Price
1.40
Quantity 806 +0.0%
Value US$1,128
2.9
Leonard Braden Michael Large shareholder
Transaction date
Purchase
Price
1.36
Quantity 55,300 +1.7%
Value US$75,108
2.9
Leonard Braden Michael Large shareholder
Transaction date
Purchase
Price
1.37
Quantity 172,747 +5.5%
Value US$236,871
2.9
Leonard Braden Michael Large shareholder
Transaction date
Purchase
Price
1.31
Quantity 150,000 +5.0%
Value US$196,950
2.9
Leonard Braden Michael Large shareholder
Transaction date
Purchase
Price
1.40
Quantity 36,176 +1.2%
Value US$50,523
2.9
Leonard Braden Michael Large shareholder
Transaction date
Purchase
Price
1.41
Quantity 100,487 +3.5%
Value US$142,008
2.9
Leonard Braden Michael Large shareholder
Transaction date
Purchase
Price
1.39
Quantity 171,339 +6.4%
Value US$238,590
2.9
Leonard Braden Michael Large shareholder
Transaction date
Purchase
Price
1.54
Quantity 335,000 +14.3%
Value US$515,900
2.9
Leonard Braden Michael Large shareholder
Transaction date
Purchase
Price
1.56
Quantity 79,281 +3.5%
Value US$123,678
2.2
Hall Ashley Chief Development Officer Officer
Transaction date
Sale
Price
6.28
Quantity 15,625 -28.3%
Value US$98,058
2.2
Hall Ashley Officer Officer
Transaction date
Proposed sale
Price
6.28
Quantity 15,625
Value US$98,058
2.3
Novo Holdings A/S 10% Stockholder Large shareholder
Transaction date
Proposed sale
Price
7.35
Quantity 100,000
Value US$735,000
2.3
Novo Holdings A/S Large shareholder
Transaction date
Sale
Price
7.10
Quantity 100,000 -2.9%
Value US$709,740
2.3
O'Donnell Niall Non-Executive Director
Transaction date
Purchase
Price
8.00
Quantity 125,000 +6.1%
Value US$1,000,000
1.4
Cruse Michael Chief Operating Officer Officer
Transaction date
Purchase
Price
3.39
Quantity 7,500 +121.0%
Value US$25,448
1.4
Cruse Michael Chief Operating Officer Officer
Transaction date
Purchase
Price
3.21
Quantity 3,212 +107.6%
Value US$10,307
1.4
Cruse Michael Chief Operating Officer Officer
Transaction date
Purchase
Price
3.19
Quantity 1,845 +161.8%
Value US$5,893
1.4
Cruse Michael Chief Operating Officer Officer
Transaction date
Purchase
Price
3.16
Quantity 975 +3.2%
Value US$3,081
1.4
Cruse Michael Chief Operating Officer Officer
Transaction date
Purchase
Price
3.24
Quantity 1,140 +inf%
Value US$3,694
1.4
Cruse Michael Chief Operating Officer Officer
Transaction date
Planned purchase
Price
3.24
Quantity 83 +0.3%
Value US$269
1.5
Muralidhar Bali Non-Executive Director
Transaction date
Purchase
Price
9.28
Quantity 20,710 +1.1%
Value US$192,245
1.5
Muralidhar Bali Non-Executive Director
Transaction date
Purchase
Price
8.72
Quantity 14,615 +0.8%
Value US$127,487
1.5
Muralidhar Bali Non-Executive Director
Transaction date
Purchase
Price
9.03
Quantity 32,659 +1.7%
Value US$294,927
1.5
Muralidhar Bali Non-Executive Director
Transaction date
Purchase
Price
9.42
Quantity 257 +0.0%
Value US$2,422
1.5
Muralidhar Bali Non-Executive Director
Transaction date
Purchase
Price
9.25
Quantity 12,100 +0.6%
Value US$111,943
1.5
Muralidhar Bali Non-Executive Director
Transaction date
Purchase
Price
9.50
Quantity 14 +0.0%
Value US$133
1.5
Muralidhar Bali Non-Executive Director
Transaction date
Purchase
Price
15.00
Quantity 200,000 +12.1%
Value US$3,000,000
2.3
Novo Holdings A/S Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 666,666 +24.1%
Value US$9,999,990
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-24 2026-06-22 PlS Planned sale
3.6
Saccomano Nicholas A

President and CEO

Executive Director
63,680 -3.4%
393.65
US$3,859,986 		63,680 -3.4% 393.65 US$3,859,986
2026-06-24 2026-06-22 PlS Planned sale
3.7
Leverone Jason A.

Chief Financial Officer

Officer
56,795 +3.9%
63.93
US$306,293 		56,795 +3.9% 63.93 US$306,293
2026-03-24 2026-03-23 S Sale
3.7
Leverone Jason A.

Chief Financial Officer

Officer
52,482 -11.1%
307.58
US$3,346,311 		52,482 -11.1% 307.58 US$3,346,311
2026-03-24 2026-03-23 S Sale
3.6
Saccomano Nicholas A

President and CEO

Executive Director
86 -1.2%
4.16
US$357 		86 -1.2% 4.16 US$357
2025-12-23 2025-12-22 PlS Planned sale
3.6
Saccomano Nicholas A

President and CEO

Executive Director
87 -1.2%
2.97
US$258 		87 -1.2% 2.97 US$258
2025-12-23 2025-12-22 PlS Planned sale
3.7
Leverone Jason A.

Chief Financial Officer

Officer
302 -1.8%
2.97
US$896 		302 -1.8% 2.97 US$896
2025-09-24 2025-09-22 S Sale
3.7
Leverone Jason A.

Chief Financial Officer

Officer
303 -2.3%
2.62
US$795 		303 -2.3% 2.62 US$795
2025-09-24 2025-09-22 S Sale
3.6
Saccomano Nicholas A

President and CEO

Executive Director
88 -2.4%
2.62
US$231 		88 -2.4% 2.62 US$231
2025-06-25 2025-06-23 S Sale
3.6
Saccomano Nicholas A

President and CEO

Executive Director
88 -2.4%
2.38
US$210 		88 -2.4% 2.38 US$210
2025-06-25 2025-06-23 S Sale
3.7
Leverone Jason A.

Chief Financial Officer

Officer
303 -2.3%
2.38
US$722 		303 -2.3% 2.38 US$722
2025-05-19 2025-05-15 S Sale
3.7
Cormorant Asset Management, LP

Former 10% Owner
1,813,439 -100.0%
1.85
US$3,363,023 		1,813,439 -100.0% 1.85 US$3,363,023
2025-05-19 2025-05-15 B Purchase
3.2
ACORN BIOVENTURES, L.P.
Large shareholder
1,129,730 +inf%
1.85
US$2,090,000 		1,129,730 +inf% 1.85 US$2,090,000
2025-05-19 2025-05-15 B Purchase
3.2
ACORN BIOVENTURES, L.P.
Large shareholder
270,270 +18.8%
1.85
US$500,000 		270,270 +18.8% 1.85 US$500,000
2025-05-14 2025-05-12 S Sale
3.7
Cormorant Asset Management, LP
Large shareholder
24,300 -1.3%
1.99
US$48,236 		24,300 -1.3% 1.99 US$48,236
2025-04-08 2025-04-07 S Sale
3.6
Saccomano Nicholas A

President and CEO

Executive Director
516 -12.3%
2.67
US$1,378 		516 -12.3% 2.67 US$1,378
2025-04-08 2025-04-07 S Sale
3.7
Leverone Jason A.

Chief Financial Officer

Officer
1,844 -12.3%
2.67
US$4,925 		1,844 -12.3% 2.67 US$4,925
2025-04-08 2025-04-04 S Sale
3.6
Saccomano Nicholas A

President and CEO

Executive Director
358 -7.9%
3.33
US$1,191 		358 -7.9% 3.33 US$1,191
2025-04-08 2025-04-04 S Sale
3.7
Leverone Jason A.

Chief Financial Officer

Officer
1,278 -7.8%
3.33
US$4,253 		1,278 -7.8% 3.33 US$4,253
2024-09-26 2024-09-25 B Purchase
2.9
Leonard Braden Michael
Large shareholder
68,746 +2.0%
1.50
US$102,872 		68,746 +2.0% 1.50 US$102,872
2024-09-26 2024-09-24 B Purchase
2.9
Leonard Braden Michael
Large shareholder
29,600 +0.9%
1.41
US$41,866 		29,600 +0.9% 1.41 US$41,866
2024-09-19 2024-09-18 B Purchase
2.9
Leonard Braden Michael
Large shareholder
806 +0.0%
1.40
US$1,128 		806 +0.0% 1.40 US$1,128
2024-09-19 2024-09-17 B Purchase
2.9
Leonard Braden Michael
Large shareholder
55,300 +1.7%
1.36
US$75,108 		55,300 +1.7% 1.36 US$75,108
2024-09-16 2024-09-16 B Purchase
2.9
Leonard Braden Michael
Large shareholder
172,747 +5.5%
1.37
US$236,871 		172,747 +5.5% 1.37 US$236,871
2024-09-16 2024-09-13 B Purchase
2.9
Leonard Braden Michael
Large shareholder
150,000 +5.0%
1.31
US$196,950 		150,000 +5.0% 1.31 US$196,950
2024-09-16 2024-09-12 B Purchase
2.9
Leonard Braden Michael
Large shareholder
36,176 +1.2%
1.40
US$50,523 		36,176 +1.2% 1.40 US$50,523
2024-08-14 2024-08-14 B Purchase
2.9
Leonard Braden Michael
Large shareholder
100,487 +3.5%
1.41
US$142,008 		100,487 +3.5% 1.41 US$142,008
2024-08-14 2024-08-13 B Purchase
2.9
Leonard Braden Michael
Large shareholder
171,339 +6.4%
1.39
US$238,590 		171,339 +6.4% 1.39 US$238,590
2024-05-16 2024-05-14 B Purchase
2.9
Leonard Braden Michael
Large shareholder
335,000 +14.3%
1.54
US$515,900 		335,000 +14.3% 1.54 US$515,900
2024-05-16 2024-05-14 B Purchase
2.9
Leonard Braden Michael
Large shareholder
79,281 +3.5%
1.56
US$123,678 		79,281 +3.5% 1.56 US$123,678
2023-08-29 2023-08-28 S Sale
2.2
Hall Ashley

Chief Development Officer

Officer
15,625 -28.3%
6.28
US$98,058 		15,625 -28.3% 6.28 US$98,058
2023-08-28 2023-08-28 PrS Proposed sale
2.2
Hall Ashley

Officer

Officer
15,625
6.28
US$98,058 		15,625 6.28 US$98,058
2023-06-23 2023-06-23 PrS Proposed sale
2.3
Novo Holdings A/S

10% Stockholder

Large shareholder
100,000
7.35
US$735,000 		100,000 7.35 US$735,000
2023-06-23 2023-06-23 S Sale
2.3
Novo Holdings A/S
Large shareholder
100,000 -2.9%
7.10
US$709,740 		100,000 -2.9% 7.10 US$709,740
2023-05-10 2023-05-08 B Purchase
2.3
O'Donnell Niall
Non-Executive Director
125,000 +6.1%
8.00
US$1,000,000 		125,000 +6.1% 8.00 US$1,000,000
2022-09-02 2022-09-01 B Purchase
1.4
Cruse Michael

Chief Operating Officer

Officer
7,500 +121.0%
3.39
US$25,448 		7,500 +121.0% 3.39 US$25,448
2022-08-31 2022-08-31 B Purchase
1.4
Cruse Michael

Chief Operating Officer

Officer
3,212 +107.6%
3.21
US$10,307 		3,212 +107.6% 3.21 US$10,307
2022-08-31 2022-08-30 B Purchase
1.4
Cruse Michael

Chief Operating Officer

Officer
1,845 +161.8%
3.19
US$5,893 		1,845 +161.8% 3.19 US$5,893
2022-08-31 2022-08-30 B Purchase
1.4
Cruse Michael

Chief Operating Officer

Officer
975 +3.2%
3.16
US$3,081 		975 +3.2% 3.16 US$3,081
2022-08-31 2022-08-29 B Purchase
1.4
Cruse Michael

Chief Operating Officer

Officer
1,140 +inf%
3.24
US$3,694 		1,140 +inf% 3.24 US$3,694
2022-08-31 2022-08-29 PP Planned purchase
1.4
Cruse Michael

Chief Operating Officer

Officer
83 +0.3%
3.24
US$269 		83 +0.3% 3.24 US$269
2021-06-25 2021-06-23 B Purchase
1.5
Muralidhar Bali
Non-Executive Director
20,710 +1.1%
9.28
US$192,245 		20,710 +1.1% 9.28 US$192,245
2021-06-23 2021-06-22 B Purchase
1.5
Muralidhar Bali
Non-Executive Director
14,615 +0.8%
8.72
US$127,487 		14,615 +0.8% 8.72 US$127,487
2021-06-23 2021-06-21 B Purchase
1.5
Muralidhar Bali
Non-Executive Director
32,659 +1.7%
9.03
US$294,927 		32,659 +1.7% 9.03 US$294,927
2021-06-07 2021-06-04 B Purchase
1.5
Muralidhar Bali
Non-Executive Director
257 +0.0%
9.42
US$2,422 		257 +0.0% 9.42 US$2,422
2021-06-07 2021-06-03 B Purchase
1.5
Muralidhar Bali
Non-Executive Director
12,100 +0.6%
9.25
US$111,943 		12,100 +0.6% 9.25 US$111,943
2021-06-02 2021-05-28 B Purchase
1.5
Muralidhar Bali
Non-Executive Director
14 +0.0%
9.50
US$133 		14 +0.0% 9.50 US$133
2021-04-15 2021-04-13 B Purchase
1.5
Muralidhar Bali
Non-Executive Director
200,000 +12.1%
15.00
US$3,000,000 		200,000 +12.1% 15.00 US$3,000,000
2021-04-15 2021-04-13 B Purchase
3.0
New Enterprise Associates 15, L.P.
Large shareholder
666,666 +16.2%
15.00
US$9,999,990 		666,666 +16.2% 15.00 US$9,999,990
2021-04-14 2021-04-13 B Purchase
2.3
Novo Holdings A/S
Large shareholder
666,666 +24.1%
15.00
US$9,999,990 		666,666 +24.1% 15.00 US$9,999,990
Explore more

More insider trading research around Onkure Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America